Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Turning a good scientific idea into a successful biotech startup is a challenging journey.
What are the steps to building a successful biotech startup? How do startup founders find grants or investors to help them build their dreams?
This panel will highlight several successful programs that scientists can use when creating a successful biotech company. Learn what resources are available to turn your idea into a business and help you develop entrepreneurial skills.
The event will introduce funding and strategic programs available from IndieBio, the Center for Biotechnology, and SVB Startup Banking Life Sciences. Featuring Phuong Nguyen, Commercialization Fellow at the Center for Biotechnology; Stephen Chambers, Managing Director and Partner of IndieBio in New York and Anton Xavier, Director for Startup Life Science Banking in NY and the Northeast at SVB Financial Group.
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2219
[post_author] => 3
[post_date] => 2016-05-27 14:46:48
[post_date_gmt] => 2016-05-27 14:46:48
[post_content] => MIDI Medical Product Development, recently cut the ribbon new headquarters in a newly constructed Medical Center of Excellence, within Smithtown’s Village of the Branch.
The 15,100 square foot facility is accelerating MIDI’s rapid growth and presence in the medical/healthcare product development industry. The site was chosen based upon its pristine location, professional environment, and proximity to their collaborating partner Stony Brook University Medical Center.
MIDI specializes in meeting FDA regulatory standards for medical devices and provides market research and product engineering and design services for the biotech and medical industries.
[post_title] => MIDI Opens New Long Island Headquarters
[post_excerpt] => MIDI Medical Product Development, recently cut the ribbon new headquarters in a newly constructed Medical Center of Excellence, within Smithtown’s Village of the Branch.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => midi-opens-new-long-island-headquarters
[to_ping] =>
[pinged] =>
[post_modified] => 2016-06-07 14:56:29
[post_modified_gmt] => 2016-06-07 14:56:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2219
[menu_order] => 180
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4231
[post_author] => 4
[post_date] => 2023-07-10 12:37:00
[post_date_gmt] => 2023-07-10 16:37:00
[post_content] =>
SBU Startup, Lahara Bio, presented in the start-up stadium event at the 2023 BIO International Convention in June.
Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus presented on behalf of Lahara after securing a spot in the coveted forum by winning multiple pitch competitions from NIH SEED office.
According to Ashdown, “Bio 2023 was an amazing experience, and I was thrilled to be able to share the exciting work that we're doing at Lahara Bio with the greater bioscience community. The CfB was incredibly helpful in preparing the company for this conference and has done an excellent job of helping me develop on a personal/professional level".
In addition to the main stage presentation, Ashdown also presented Lahara Bio at the NIH booth. Lahara Bio was sponsored to attend BIO by the NIH after Ashdown won the national investor pitch competition at the NIH Proof of Concept Network annual meeting this past spring.
Lahara Bio is an early-stage biotechnology company using cell-specific mechanical vibration to non-invasively improve biomanufacturing outcomes. Learn more about the company and the team behind Lahara at laharabio.com.
[post_title] => Lahara Bio Presents at BIO International Convention
[post_excerpt] => Stony Brook Start Up, Lahara Bio, was presented at the 2023 BIO International Convention by Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lahara-bio-presents-at-bio-international-convention
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:32:58
[post_modified_gmt] => 2024-08-22 15:32:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4231
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4051
[post_author] => 4
[post_date] => 2023-03-16 14:01:07
[post_date_gmt] => 2023-03-16 14:01:07
[post_content] =>
The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies through our commercialization assistance program, Concept to Clinic: Commercializing Innovation Education (e-C3i). This program provides entrepreneurial education for investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The eC3i course is being offered to investigators with active (or in a No-Cost Extension through 9/23) NIH-funded research projects from participating Institutes and Centers.
All applications must be received no later than April 14th, 2023. Apply Today! Applications can be submitted to NIBIB-SBIR@mail.nih.gov. All NHLBI grantees are encouraged to contact us (nhlbi_sbir@mail.nih.gov) if you are interested in participating or have any questions about the application process. Learn more here.
[post_title] => NIH Grantees: Learn How to Commercialize Your Tech
[post_excerpt] => The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-ec3i-2023
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:34:34
[post_modified_gmt] => 2024-08-22 15:34:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4051
[menu_order] => 5
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
